is semaglutide long acting New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists FORMULATION DEVELOPMENT - Innovative Drug

M., Kurzer, M

Kushner was an investigator in the STEP trials and serves on the Global and National Advisory Board for Novo Nordisk for which he receives compensation

If you are ready to take the next step in your health journey, complete the free assessment quiz to help determine which personalized program may be right for your unique health profile

According to the UK Summary of Product Characteristics (SmPC), nausea occurred in approximately 1221% of patients receiving dulaglutide in the AWARD clinical trial programme, compared with higher rates observed with some other agents

Taking more than the recommended amount can increase the risk of an overdose